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Multiple sclerosis (MS) is an autoimmune disorder in which the body’s immune cells attack nerves in 
the brain and spinal cord. Nerve damage is mediated by inflammation and immune cell-mediated 
destruction of myelin, a protective protein surrounding neurons. As a result, nerve impulses are 
slowed or stopped, resulting in a multitude of symptoms including: impaired muscle and cognitive 
functions, loss of bowel and bladder control, difficulty seeing and fatigue. Generally, the symptoms of 
MS occur during acute episodes called relapses, which are separated by remission periods that are 
relatively free of disease symptoms. In progressive MS disease, neurologic functions continue to 
decline over time. Current treatments for MS are aimed at limiting the magnitude and frequency of 
attacks and improving quality of life, but no cures exist for patients. Immunosuppressants have been 
successfully used to minimize disease symptoms in relapsing patients, but are only partially capable 
of reducing the frequency of relapses and are not effective against progressive disease. 
High-dose immunotherapy (HDIT) followed by autologous hematopoietic stem cell transplants 
(AHCT) has been successfully used to treat other autoimmune disorders, as well as disease in 
animal models of MS. To determine the efficacy of HDIT/AHCT for treatment of MS, researchers in 
the Clinical Research Division examined the ability of HDIT/AHCT to induce sustained remission 
from autoimmune events and to prevent further loss of neurological function in 26 patients with 
severe MS. Patients represented a heterogeneous group with severe progressive MS who had 
limited success with an array of prior therapies. HDIT was used to deplete autoreactive lymphocytes 
that contribute to MS pathogenesis, and consisted of a regimen of total body irradiation, high-doses 
of the cytotoxic chemotherapeutic agent cyclophosphamide and in vivo T-cell depletion. Patients 
were subsequently infused with lymphocyte-depleted autologous peripheral blood stem cells that 
were obtained prior to HDIT. Together, these treatments ablate autoimmune lymphocytes and permit 
regeneration of a self-tolerant immune system from T-cell-depleted stem cells. 
Follow-up evaluations measured the patients’ disability status, the extent of brain lesions, and the 
presence of oligoclonal immunoglobulin bands in the cerebral spinal fluid as a measure of  
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inflammation in the central nervous system. Nash and colleagues in the Clinical Research Division 
previously reported the initial patient evaluations, generally describing mild to moderate regimen-
related toxicities, which were transient and reversible. Despite the severe stage of MS and extensive 
brain damage and loss of neurological function of patients prior to HDIT/AHCT, stabilization of 
disease was observed in the majority of patients. Furthermore, important modifications of the 
treatment protocol were also identified to increase the safety of HDIT/AHCT for patients. 
In the current publication, Bowen et al report on the long-term evaluation of patients following 
HDIT/AHCT treatment. A significant number of patients remained stable up to six years post 
treatment, with few late side effects of immunotherapy. However, some patients demonstrated 
worsening neurological function, which was associated with an increased level of disability at 
initiation of the study. Additionally, many patients whose MS worsened did not show signs of 
increased CNS inflammation or brain lesions, suggesting that other disease mechanisms may be 
responsible for disease progression. Together these results indicate that HDIT/AHCT is a useful 
treatment option for some patients with MS, and that similar studies are warranted in patients with 
less severe MS. Randomized studies examining the clinical role of HDIT and AHCT in comparison 
with conventional MS treatments will also be important. 
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